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ABSTRACT 
 
 
POTENTIAL FOR IMMUNOPROTECTION OF PANCREATIC ISLETS BY COVALENT 
MODIFICATION WITH POLY(ETHYLENE GLYCOL) 
 
Carl L. Engman, MS 
 
University of Pittsburgh, 2002 
 
 
Diabetes Mellitus is one of the predominant contributors to morbidity and mortality worldwide.  
Prior to the advent of insulin therapy, patients suffering from Type I diabetes generally did not survive 
past childhood.  Even with insulin therapy, a physiologically normal insulin response to increased 
systemic glucose cannot be achieved.  Pancreatic islet transplantation has been shown to restore the 
physiological response to glucose, but risks associated with chronic immune suppression outweigh the 
benefit of tighter glucose regulation.  This study investigates the potential of covalent modification of 
pancreatic islets with poly(ethylene glycol) (PEG) to abrogate the immune response towards transplanted 
islets and eliminate the need for chronic immune suppression.  Previous studies have shown that PEG can 
be covalently bound to islet extracellular matrix (ECM) and surface proteins with no adverse affect on 
islet viability or function.  The goal of this study was to determine the effect of covalent PEG 
modification on binding of islet-specific antibody, and to determine whether or not PEG modification 
could prolong graft survival in vivo.  By a novel adaptation of an enzyme-linked immunosorbent assay 
(ELISA) the amount of islet-specific antibody bound to unmodified or PEG-modified islets was compared 
semi-quantitatively.  Islets treated with 40kD branched PEG-NHS bound significantly more antibody than 
untreated controls.  Based on the student’s paired t-test there was no statistically significant change in 
antibody binding between 5kD PEG-treated and unmodified islets, although 7 of 9 PEG treated groups in 
this experiment bound less antibody than the corresponding unmodified groups.  For in vivo islet 
transplantation , there was no difference in graft survival observed between PEG-treated and untreated 
grafts.  Although PEG treatment did not have an apparent effect on in vivo graft survival, the effects 
observed in the antibody binding experiment suggest that PEG does modify antibody binding and further 
investigation of this technique is warranted. 
 iii
  
 
FOREWARD 
 
 
I would like to thank the member’s of my thesis committee, Dr. Eric Beckman, Dr. Alan 
Russell and especially Dr. William Wagner for the opportunity to do this work and for guidance 
along the way.  Thank you to Susan Dadd and Janice Panza for laying the foundation for this 
project.  Thank you to Dr. Adolfo Garcia-Ocana for help in fine-tuning my islets isolation 
technique and to Dr. Kenneth Litwak for help in working out the details of the transplantation 
study.  I would also like to thank the undergraduate students who have provided technical 
assistance: Samer Melhem, Rebecca Nick and Nicole White.  Finally, I would like to thank my 
friends and family especially my parents Bruce and Michele Engman for their love and support 
and for the encouragement I needed to get this thing done. 
 
 
 iv
  
 
 
TABLE OF CONTENTS 
 
 
FOREWARD ................................................................................................................................. iv 
1.0  INTRODUCTION ................................................................................................................... 1 
1.1  Diabetes Mellitus ................................................................................................................. 1 
1.1.1  IDDM............................................................................................................................ 1 
1.1.2  NIDDM......................................................................................................................... 2 
1.1.3  Gestational Diabetes ..................................................................................................... 2 
1.1.4  Secondary Diabetes....................................................................................................... 2 
1.2  Impact of Diabetes ............................................................................................................... 3 
2.0  BACKGROUND AND LITERATURE REVIEW ................................................................. 4 
2.1  Pancreatic Islets ................................................................................................................... 4 
2.1.1  Morphology................................................................................................................... 4 
2.1.2  Metabolic Regulatory Function of Islets....................................................................... 5 
2.2  Current Treatment Methods................................................................................................. 6 
2.2.1  Insulin Therapy ............................................................................................................. 6 
2.2.2  Transplantation ............................................................................................................. 7 
2.3  Mechanisms of Graft Rejection ........................................................................................... 7 
2.4  Strategies for Prevention or Reversal of Type I DM ........................................................... 8 
2.4.1  Interventional Therapy.................................................................................................. 8 
2.4.2  Transplantation of Encapsulated Islets ......................................................................... 8 
2.4.3  Genetic Manipulation.................................................................................................... 9 
2.4.3.1  Delivery Vehicles................................................................................................... 9 
2.4.3.2  Strategies................................................................................................................ 9 
2.5  PEG.................................................................................................................................... 10 
2.5.1  Properties of PEG ....................................................................................................... 10 
2.5.2  Previous Studies.......................................................................................................... 11 
 v
2.5.2.1  PEG Modification of Synthetic Surfaces............................................................. 11 
2.5.2.2  PEG Modification of Vascular Tissue ................................................................. 11 
2.5.2.3  PEG Treatment of Islets....................................................................................... 11 
2.5.2.4  Islet Viability Following PEG Treatment ............................................................ 12 
2.5.2.5  Islet Function Following PEG Treatment ............................................................ 12 
2.5.2.6  Complement-Mediated Lysis of PEG-Treated Islets ........................................... 13 
3.0  RESEARCH OBJECTIVES .................................................................................................. 14 
3.1  Is PEG Surface Coverage Complete?  Does PEG Enter Islet Cells?................................. 14 
3.2  Investigate Ability of PEG to Prevent Ab Attachment...................................................... 15 
3.3  Determine the Ability of PEG-Modification to Prolong Islet Graft Survival in Vivo. ...... 15 
4.0  EXPERIMENTAL PROCEDURES...................................................................................... 16 
4.1  Islets Isolation .................................................................................................................... 16 
4.2  PEG-Treatment of Islets .................................................................................................... 17 
4.3  Confocal Microscopy......................................................................................................... 18 
4.3.1  Imaging Surface Bound PEG...................................................................................... 18 
4.3.2  Two Color Imaging of PEG and Antibody Binding ................................................... 18 
4.4  Quantitative Antibody Binding Assay ............................................................................... 19 
4.5  Islet Allograft Transplantation........................................................................................... 20 
4.5.1  Induction of Diabetes.................................................................................................. 20 
4.5.2  In Vitro Islet Function................................................................................................. 20 
4.5.3  Islet Transplantation.................................................................................................... 21 
4.6  In Vivo Islet Function......................................................................................................... 21 
5.0  RESULTS .............................................................................................................................. 22 
5.1  Islet Isolation...................................................................................................................... 22 
5.2  Confocal Images ................................................................................................................ 22 
5.2.1  Effect of Increased Culture Time on Quality of PEG Binding................................... 22 
5.2.2  Effect of PEG Molecular Weight................................................................................ 23 
5.3  Confocal Microscopy of Bound Antibody......................................................................... 26 
5.4  Quantitative Ab-Binding Data ........................................................................................... 28 
5.5  In Vitro Islet Function........................................................................................................ 30 
5.6  In Vivo Islet Graft Survival ................................................................................................ 30 
 vi
6.0  DISCUSSION........................................................................................................................ 32 
6.1  Confocal Images of Bound PEG........................................................................................ 32 
6.2  Quantitative Ab-Binding Assay......................................................................................... 33 
6.3  In Vivo Transplantation Study ........................................................................................... 34 
6.4  Future Directions ............................................................................................................... 35 
Appendix A................................................................................................................................... 37 
Additional Islet Images ............................................................................................................. 37 
BIBLIOGRAPHY......................................................................................................................... 41 
 
 
 vii
  
 
 
LIST OF TABLES 
 
 
Table 1.  Abbreviations and concentrations of various PEG constructs used in this research ..... 17 
 
 
 viii
  
 
 
LIST OF FIGURES 
 
 
 
Figure 1.  Effect of Culture Time on PEG-Binding...................................................................... 24 
Figure 2.  Effect of PEG MW on PEG binding. ........................................................................... 25 
Figure 3.  Determining appropriate Ab treatment for Ab-binding experiments. .......................... 25 
Figure 4.  Simultaneous, two-color PEG/Ab images.................................................................... 27 
Figure 5.  Results of Ab-binding assay for 40 kD PEG-treated islets. ......................................... 29 
Figure 6.  Results of Ab-binding assay for 5 kD PEG-treated islets. ........................................... 29 
Figure 7.  Changes in blood glucose concentration and body mass following pancreatic islet 
transplantation....................................................................................................................... 31 
Figure 8.  Images showing presence of putative necrotic regions. ............................................... 33 
Figure 9.  Images of islets modified with 80kD PEG-FITC......................................................... 37 
Figure 10.  Images of islets modified with 40kD PEG-FITC, after six days in culture. .............. 38 
Figure 11.  Images of islets modified with 5kD PEG-FITC. ........................................................ 39 
 
 
 
 
 ix
  
 
 
1.0  INTRODUCTION 
 
 
 
 
1.1  Diabetes Mellitus 
 
 
 
 Diabetes Mellitus (DM) is a general term describing one of four metabolic disorders that 
result in an abnormal elevation in blood glucose concentration.  At the root of these disorders is 
an insufficiency in insulin secretion or an inability of insulin-responsive tissues to sense insulin.  
The result is inefficient carbohydrate metabolism and accumulation of glucose in the blood.1 
 
 
 
1.1.1  IDDM 
 
 
 
 Insulin dependent diabetes mellitus (IDDM, juvenile diabetes, Type I DM) is 
characterized by almost complete cessation of insulin production.  It is caused by autoimmune 
destruction of the beta-cells of the pancreatic islets, the cells responsible for producing and 
secreting insulin in response to glucose challenge.1  
 The factors influencing the onset of this disease are not fully understood.  It is accepted 
that there is a genetic predisposition to the disease, but as the probability of two identical twins 
developing Type I DM is only 30 – 50%, it is clear that environmental factors also play a role.2   
Evidence of a possible environmental trigger is a correlation between exposure to cow’s milk in 
infancy and increased occurrence of Type I DM.  It is believed that an immune reaction with 
1 
 bovine albumin may lead to the production of antibodies reactive with a cell surface protein 
present on islet beta-cells that resembles bovine albumin.3 
 
 
 
1.1.2  NIDDM 
 
 
 
 In non-insulin dependent diabetes mellitus (NIDDM, adult onset diabetes, Type II DM) 
hyperglycemia results from resistance to insulin action and may be accompanied by 
hyperinsulinemia and eventually loss of beta-cell mass.1,4  Risk factors include obesity and a 
sedentary lifestyle among others.  In obesity, a marked overproduction of insulin is observed.1  
This may set the stage for development of insulin resistance.  Eventually glucose ceases to be a 
stimulus for insulin release.  This lack of islet activity may lead to beta-cell death. 
 
 
 
1.1.3  Gestational Diabetes 
 
 
 
 Gestational diabetes is a result of overcompensation in insulin resistance during 
pregnancy.  During a normal pregnancy, insulin action is suppressed somewhat in the mother to 
allow glucose to pass to the developing fetus.  If insulin action is suppressed too much the 
mother will experience hyperglycemia. 
 
 
 
1.1.4  Secondary Diabetes 
 
 
 
 Secondary diabetes refers to a hyperglycemic condition caused by exogenous factors.  
Cancer, infection requiring pancreatectomy, or exposure to certain chemicals such as 
2 
 streptozotocin result in loss of islet beta-cells and insufficient insulin production.  Other 
chemicals or drugs may suppress insulin secretion or insulin action.1 
 
 
 
 
1.2  Impact of Diabetes 
 
 
 
 Of the two major forms of DM (Types I & II) Type II DM is generally more severe.  
Acute symptoms include polyuria, polyphagia, polydypsia, pruritus and excessive weight loss.  
In the absence of insulin, fats replace glucose as the primary energy source.  In severe cases, 
ketone products of fat metabolism accumulate in the blood resulting in ketoacidosis, coma and 
death.1 
 The chronic effects of hyperglycemia can also be devastating.  Poorly controlled blood 
glucose has been linked to nephropathy from osmotic overload, loss of eyesight, atherosclerosis 
and neuropathy. 
 Based on a survey conducted in 1995 by The American Diabetes Association, ~6% of the 
population of US suffers from diabetes.  Of these, 5 – 10 % have Type I diabetes or IDDM.  
Thirty thousand new IDDM cases are diagnosed each year. Diabetes is the leading cause of end-
stage renal disease, accounting for about 40% of new cases. Diabetes is the leading cause of new 
cases of blindness in people ages 20-74. Each year, from 12,000 to 24,000 people lose their sight 
because of diabetes.  People with diabetes are 2 to 4 times more likely to have heart disease 
which is present in 75 percent of diabetes-related deaths.  The risk of a leg amputation is 15-40 
times greater for a person with diabetes. Each year, more than 56,000 amputations are performed 
among people with diabetes.  All told, diabetes and the complications associated with chronic 
hyperglycemia constitute one of the largest causes of morbidity and mortality worldwide. 
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2.0  BACKGROUND AND LITERATURE REVIEW 
 
 
 
 
2.1  Pancreatic Islets 
 
 
 
 The Islets of Langerhans are endocrine suborgans which reside in the pancreas.  They 
constitute ~1–2% of total pancreas volume.  The hormones released by pancreatic islets, insulin, 
glucagon, somatostatin and pancreatic polypeptide all play important roles in the regulation of 
metabolism.  The anatomical position of the pancreas, just upstream from the liver, reflects this 
function.1 
 
 
 
2.1.1  Morphology 
 
 
 
 Islets are heterogeneous in nature.  Each islet is composed of two or three of four possible 
cell types, alpha-cells, beta-cells, delta-cells, and pancreatic polypeptide-cells.  Every islet 
contains a core of beta-cells surrounded by a mantle of either alpha and/or delta cells or a mantle 
of delta and PP cells.  In some species (rat, human, canine) the mantle is enclosed by a capsule 
composed of collagenous ECM and a monolayer of fibroblasts.  Porcine islets do not possess this 
collagenous capsule.5 
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 2.1.2  Metabolic Regulatory Function of Islets 
 
 
 
 As mentioned previously, the islet beta-cells are solely responsible for sensing the 
glucose concentration in the blood and releasing insulin in response.  The mechanism is as 
follows.  The glut2 receptor, present on beta-cells, allows diffusion of glucose into the cells, 
maintaining intracellular glucose concentration at the same level as the surrounding extracellular 
fluid.  An enzyme, glucokinase, acts as a chemical sensor for glucose.  Phosphorylation of 
glucose is the rate limiting step in glucose oxidation in beta-cells.  As glucose is oxidized, the 
intracellular ATP concentration rises.  At a critical ATP concentration, ATP sensitive K+ 
channels open, initiating depolarization of the cell membrane.  This depolarization triggers an 
influx of Ca++ through voltage-gated Ca++ channels.  Ca++ is a second messenger that initiates 
movement of insulin secretory granules along the microtubules and leads to insulin secretion.  
The primary action of insulin is on muscle and fatty tissue.  Insulin signals these tissues to take 
up and use or store glucose from the blood. 
 Islet alpha-cells secrete glucagon.  Although not as crucial to survival as insulin, 
glucagon also plays an important role in fine-tuning blood glucose concentration.  Glucagon acts 
in opposition to insulin at times when glucose must be liberated from endogenous stores.  It 
triggers the release of glucose from carbohydrate stores in the liver and initiates gluconeogenesis, 
or conversion of proteins and fats to glucose.  It also suppresses insulin release.  The delta-cells 
release somatostatin which suppresses both insulin and glucagon release.  The PP-cells release 
pancreatic polypeptide.  The role of this hormone is not fully understood.1 
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 2.2  Current Treatment Methods 
 
 
 
 Although therapies have been devised to manage hyperglycemia, complete and 
permanent reversal of diabetes has only been achieved in certain exceptional cases. 
 
 
 
2.2.1  Insulin Therapy 
 
 
 
 Insulin therapy is, by far, the most common form of treatment for management of Type I 
DM.  When replacement of endogenous insulin with subcutaneous injections of bovine insulin 
was found to be effective in lowering blood glucose concentration in 1922, it represented the first 
major breakthrough in the treatment of a previously untreatable disease.  Since this initial 
discovery, methods of producing and extracting insulin have been improved.  New formulations 
for exogenous insulin, have been created to vary the time course of insulin action and provide 
both for longer-term baseline insulin requirements and transient insulin requirements following 
meals.1  Despite these advances, insulin therapy leaves much to be desired.  Because of the rapid 
response of islets to slight variations in glucose concentration, it is impossible to mimic the 
physiological response by delivery of exogenous insulin.1   In addition, the quality of glucose 
control is left entirely up to the patient.  Adequate glucose regulation requires frequent 
monitoring by finger prick and subcutaneous insulin injections three or more times daily.   
 The advent of the implantable insulin pump eliminates the need for frequent shots, but 
still requires careful monitoring and input from the patient.  Therefore, patient error still comes 
into play. 
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 2.2.2  Transplantation 
 
 
 
 Transplantation of insulin producing tissues (whole pancreas or pancreatic islets) seems 
to be the most logical solution for reversal of diabetes.  In successful transplants, regulation of 
glucose metabolism closely follows the native physiological response.  The applicability of these 
procedures is, however, limited.  The morbidity associated with chronic immune suppression 
outweighs the benefit of tighter glucose regulation.  For this reason, pancreas or pancreatic islet 
transplants are generally only performed along with another more immediately necessary organ 
transplant.  An additional problem associated with pancreas transplant is the chronic release of 
digestive enzymes into the peritoneal cavity resulting in significant morbidity.6,7  Even with the 
most refined peri-transplant protocols, islet transplant success rate at one year does not exceed 
20%.6 
 
 
 
 
2.3  Mechanisms of Graft Rejection 
 
 
 
 Rejection of allo-transplanted tissue grafts is most commonly associated with a response 
by CD8+, cytotoxic, T cells or CD4+, helper T cells or both.  Antibodies can also play a role in 
“second set” rejection, or rejection following prior sensitization.8  Therefore, in order to 
eliminate the need for chronic immunosuppression after islet transplant, it is necessary to devise 
a means to interfere with these immune mechanisms. 
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 2.4  Strategies for Prevention or Reversal of Type I DM 
 
 
 
2.4.1  Interventional Therapy 
 
 
 
 Interventional approaches to treating type I DM fall into three categories.  Primary 
prevention involves identifying and eliminating environmental risk factors (viruses, chemicals, 
components of diet) from a normal population.  Considering the possible correlation between 
ingestion of bovine albumin in infancy and incidence of type I DM, an example of primary 
prevention would be a recommendation for mothers to avoid exposing their infant children to 
cow’s milk, especially if there is a family history of type I DM. 
 Secondary prevention involves early identification of symptoms of the onset, and 
intervention prior to full development of the disease.  Tertiary prevention attempts to deal with 
clinical complications associated with disease onset.9 
 
 
 
2.4.2  Transplantation of Encapsulated Islets 
 
 
 
 The rationale behind this strategy is that a perm-selective membrane surrounding the islet 
may shield it from attack by humoral components of the immune system, such as antibodies and 
complement proteins, and the phagocytic and cytotoxic immune cells.  Many studies have shown 
that encapsulation in a perm-selective membrane can prolong allo- or xeno- graft survival in 
diabetic animals.10-20   
 Choice of material for encapsulation is crucial.  First, the material must selectively 
exclude large molecules such as antibodies while allowing diffusion of insulin, glucose, oxygen 
and metabolic waste.  The membrane must be sufficiently strong to resist breaking.  It must also 
be chemically and biologically compatible to elicit the smallest possible inflammatory response 
and to ensure islet viability and proper function.  Materials used for encapsulation include 
8 
 complex coacervates of alginate and poly-L-lysine, hydrogels of agarose, photopolymerizable 
PEG, and PEG, acrylic hollow fibers, tissue-engineered membranes of autologous chondrocytes, 
and others.10-20 
 The most commonly used encapsulation material for pancreatic islets is a complex 
coacervate composed of alternating layers of alginate and poly-L-lysine. 
 The primary failure mode is cellular overgrowth onto the capsule material.  This effects 
the mass transport properties of the capsule and leads to asphyxiation of the encapsulated cells.21 
 
 
 
2.4.3  Genetic Manipulation 
 
 
 
2.4.3.1  Delivery Vehicles. Because the islet beta-cells do not replicate, it is necessary to use a 
vehicle capable of delivering genes to quiescent cells.  The most likely candidates are viral 
vectors of one of the following types: 1) Replication defective adenovirus, 2) Herpes simplex-1, 
or 3) lentiviral vectors.  At this point however, none of these systems has been proven to be 
efficacious, stable, or safe enough for clinical use.  Adenoviral vectors and the herpes simplex 
virus are not retroviruses, therefore the gene products they deliver remain episomal and never 
incorporated into the cell’s genome.  Additionally, expression of some viral proteins may elicit 
an immune response and target the transfected cells for removal.7 
Lentiviral vectors (e.g. HIV-1) do incorporate their genes into the cell’s genome for more 
stable expression, and do not elicit an immune response, but issues of safety have not been 
addressed.7 
 
 
2.4.3.2  Strategies. Many strategies have been envisaged to modify the immune response 
towards transplanted islets by gene therapy.  For example, islets are extremely sensitive to the 
oxidative environment in an inflammatory site.  A reduction in local oxidant stress by 
transfection of islet cells with genes encoding antioxidants such as thioredoxin or manganese 
superoxide dismutase may prolong graft survival.36-38 
 It has been observed that increased tryptophan catabolism may be responsible for 
maternal tolerance of the fetus, although the mechanism is, as yet, unclear.  Transfection with 
9 
 genes encoding indoleamine 2,3 dioxygenase, a catalyst of tryptophan, may create a local 
environment with some of the immune properties of the womb during pregnancy.39 
 Finally, expression of anti-inflammatory cytokines or anti-complement agents such as 
decay accelerating factor may act to undo the immune stimulation caused by foreign islet tissue.7 
 
 
 
 
2.5  PEG 
 
 
 
2.5.1  Properties of PEG 
 
 
 
 Poly(ethylene glycol) (PEG) is a polymer derived from ethylene oxide monomers.  It is 
non-toxic and non-inflammatory and has gained FDA approval for internal use.  Because the 
structure of PEG allows water to maintain its hydrogen bonding structure in aqueous solution, it 
is extremely hydrophilic and is entropically favored to maintain a fully hydrated, extended chain 
formation.  The subsequently large molecular radius gives PEG the ability to sterically repel 
other molecules.22-24  These properties have lead to the investigation of PEG as a surface coating 
to improve the biocompatibility of various biomaterials.  It has also been hypothesized that the 
ability of PEG to reject protein adsorption may decrease the immunogenicity of transplanted 
tissues by isolating the tissues from access by antibodies and the cellular components of the 
immune system.25,26 
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 2.5.2  Previous Studies 
 
 
 
2.5.2.1  PEG Modification of Synthetic Surfaces. Various methods have been used to attach 
PEG to the surfaces of many materials.  The simplest method is to adsorb a PEG-containing 
surfactant to a surface.27-29  PEG can also be physically incorporated into a surface by creating a 
surface physical interpenetrating network (SPIN).30,31  PEG segments can be included in 
poly(urethane) block copolymers.  The resulting polymer has a surface enriched with PEG when 
placed in an aqueous medium.32  Glow discharge treatment with PEG results in a polymer 
surface covalently modified with PEG.33  Finally photoreactive PEG may be interfacially 
polymerized to create a conformal, cross-linked PEG coating.34  Examples of these surface 
modification methods have been shown to reduce protein and/or platelet adhesion both in vitro 
and in vivo.27-34 
 
 
2.5.2.2  PEG Modification of Vascular Tissue. Using an amine-reactive form of PEG, it is 
possible to covalently modify the surface proteins of a damaged vascular intima.  Treatment with 
amine-reactive PEG of denuded human placental artery reduced platelet adhesion in an in vitro 
perfusion assay by 89%.  In an in vivo assay of platelet adhesion in the femoral artery of rabbits 
following injury by balloon angioplasty showed a significant reduction in platelet adhesion from 
the untreated controls.22 
 
 
2.5.2.3  PEG Treatment of Islets. Based on previous studies of PEG modification of synthetic 
surfaces27-34 and of damaged vascular intima22, it was hypothesized that covalent modification of 
pancreatic islet surfaces with PEG might modify the host’s immune response towards the islets 
by preventing specific as well as nonspecific binding of antibodies and other inflammatory 
mediators at the islet surface.  PEG variants can be synthesized to terminate in one or more 
amine-reactive functional groups such as N-hydroxysuccinimide (NHS) or isocyanate.  These 
functional groups will react with proteins via free amine groups such as are found at the N-
terminus or on lysine residues within the protein.  Proteins reacted in this fashion will be 
covalently linked to the PEG chain. 
11 
  In one study of the efficiency of PEG-binding at the islet surface, the investigator used an 
avidin-biotin linking system to fluorescently label PEG following PEG treatment.  The islets 
were then imaged using a confocal microscope.  Images showed a high degree of fluorescent 
labeling at the islet surfaces.25,26  However, the ability of these images to accurately reveal the 
location of PEG binding came into question due to the nature of the linking system.  In short, due 
to the large molecular weight of avidin, used as a fluorescent tag, it was hypothesized that there 
may have been PEG throughout the islet volume that was not labeled because the avidin did not 
diffuse freely to the islet interior.   
 In subsequent experiments, a directly labeled PEG molecule was used, circumventing the 
avidin-biotin linking system.  Confocal images obtained in this manner showed that PEG was 
indeed binding in the islet interior as well as the periphery,35 but due to poor resolution of these 
images, the nature of PEG binding was still unclear.  Islets which showed the highest degree of 
fluorescent labeling appeared as though PEG may be entering individual islet cells, an 
undesirable result as PEG that is taken up into cells may have, or indicate, a toxic effect.  One 
goal of this research was to determine conclusively, the nature of PEG binding at the islet 
surfaces as well as in the interior of islets. 
 
 
2.5.2.4  Islet Viability Following PEG Treatment. It is important that the PEG treatment has no 
effect on islet viability.  A standard assay to demonstrate cell viability is a cell proliferation 
assay.  As islet cells do not divide under normal circumstances, an assay that reveals metabolic 
activity is necessary to prove islet cell viability.  Previous studies have used the mitochondrial 
MTT viability assay.  MTT is a straw yellow-colored substance which is cleaved by active 
mitochondria to form a purple-colored formazan salt in living cells.  Results of MTT assays of 
PEG-treated and untreated islets showed that there is no significant loss of viability after PEG-
treatment.35 
 
 
2.5.2.5  Islet Function Following PEG Treatment. 
 It is also important that the treatment method has no effect on proper islet function.  The 
islets must be able to respond appropriately, by releasing insulin in response to secretogogues, 
12 
 especially glucose.  Previous studies using radioimmunoassay for insulin showed that there was 
no significant difference in glucose response of PEG-treated and untreated islets.35 
 
 
2.5.2.6  Complement-Mediated Lysis of PEG-Treated Islets. To begin investigation of the 
immunoprotective effect of a PEG-coating on pancreatic islets, a previous study used an in vitro, 
complement-mediated lysis experiment.  In short, islets, either untreated or treated with PEG 
were incubated in wells of a 96 well microtiter plate overnight in a solution containing rabbit 
anti-rat islet antiserum.  Controls included medium without antiserum, naïve rabbit serum, rat 
serum and methanol (a negative control).  Following incubation, the viability of the islets was 
tested using the MTT cell viability assay.  Results from this experiment were somewhat 
anomalous.  It was expected that in wells that did not contain anti-rat islet antibodies, that 
viability would be similar between the PEG-treated and untreated groups.  However, a 
significant reduction in viability in the PEG-treated group was observed for groups tested in 
naïve rabbit serum, rat serum and standard cell culture medium.  This suggested to the 
investigator that there was a toxic effect on the islets during the PEG-treatment process, in 
contrast to an earlier study.25,26  In groups of islets that were tested with antiserum, no significant 
change in viability was found between PEG-treated and untreated groups.  Since islet viability 
was somewhat depressed in all PEG-treated groups, but there was no additional decrease in 
viability from control in the antiserum tested groups it was hypothesized that for islets that 
survived the treatment process, the PEG had somewhat of a protective effect.35  However, the 
possibility of cross-contamination of all the wells in a plate containing volatile methanol was 
overlooked.  Since methanol was used in some but not all of the runs of the experiment, there is 
an artificial and unpredictable depression in the viability reported and these data may not be 
valid. 
13 
  
 
 
3.0  RESEARCH OBJECTIVES 
 
 
 
 Previous studies have shown the potential usefulness of a covalently bound surface PEG 
layer to prevent rejection of pancreatic islets.25,26,35  Covalent modification does not reduce 
viability or function of islets in vitro.25,26  There is also some evidence that the PEG layer may 
reduce complement-mediated lysis of islet cells exposed to xenogeneic islet antiserum.35  
However, questions still remain regarding the degree of coverage that is achieved by the 
treatment procedure, and the clinical usefulness of this process. The question as to whether the 
PEG coating is enough to significantly prolong graft survival in vivo has not yet been answered. 
 
 
 
 
3.1  Is PEG Surface Coverage Complete?  Does PEG Enter Islet Cells? 
 
 
 
 Previous studies have suggested the possibility of “hotspots” or areas on the islet surface 
where PEG coverage is not complete.25,26  A subsequent study showed that more complete 
coverage could be achieved, but there was also evidence that some islets were becoming 
saturated with PEG.35  Due to low resolution of the confocal images in this previous study, the 
quality of PEG binding was unclear.  One goal of the current research was to answer these 
questions regarding the quality of PEG binding. 
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 3.2  Investigate Ability of PEG to Prevent Ab Attachment 
 
 
 
 A previous study showed a possible protective effect of the PEG coating against 
complement-active antiserum.  However, due to possible cross-contamination of test wells by 
methanol in adjacent, negative control wells, this data is unclear.  In this study the ability of PEG 
to reject islet-specific antibodies will be investigated further. 
 
 
 
 
3.3  Determine the Ability of PEG-Modification to Prolong Islet Graft Survival in Vivo. 
 
 
 
 Although previous studies have investigated the potential of covalent PEG modifcation to 
prolong pancreatic islet graft survival, none have addressed this issue directly.  The final goal of 
this project was to determine whether or not PEG-modification can prolong graft survival in 
vivo. 
15 
  
 
 
4.0  EXPERIMENTAL PROCEDURES 
 
 
 
 
4.1  Islets Isolation 
 
 
 
 Pancreatic islets were isolated from 300 – 450 g male Sprague-Dawley rats by a modified 
intraductal collagenase digestion method.  The pancreases were distended in vivo by injection via 
the common bile duct of 15 mL of ice-cold collagenase (Collagenase P, Boehringer Mannheim) 
solution.  The collagenase solution was prepared at a concentration of 1.7 mg/mL in cold Hank’s 
Balanced Salt Solution (HBSS) and sterile filtered.  The pancreases were then excised and 
collected in separate 50 mL Falcon tubes.  Collagenase solution was added to bring the total 
volume of each tube to ~7.5 mL.  The tubes were placed in a 37 C water bath for ~20 – 25 min.  
Digestion time varied depending on lot number and activity of collagenase.  The tissue digest 
was vortexed briefly to release the islets.  The reaction was quenched by addition of 35 mL cold 
HBSS (w/out Ca2+ & Mg2+, supplemented with 10% FBS) (HBSS+FBS).  The contents of the 
tubes were washed 3 times with cold HBSS+FBS then filtered through an 800 um wire mesh to 
remove undigested tissue.  The tissue digest was pelleted by centrifugation then resuspended in 
15 mL Ficoll-Paque solution (Pharmacia) and overlaid with 13 mL HBSS.  The islets were then 
separated by centrifugation at 700 xg for ten min at 5 C.  Islets were removed from the boundary 
layer and washed three times with HBSS+FBS.  The islets were further purified by handpicking 
under a microscope and cultured in CMRL 1066 medium (Gibco supplanted w/ 1% Penicillin-
Streptomycin and 10% FBS). 
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 Table 1.  Abbreviations and concentrations of various PEG constructs used in this research 
 
 
Type Abbreviation Concentration 
5kD linear PEG-NHS 5kD-PEG 5 mg/mL 
5kD linear flourescein-PEG-NHS 5kD-PEG-FITC 5 mg/mL 
40kD 8-arm NHS branched PEG 40kD-PEG 25 mg/mL 
40kD 7-arm NHS, 1-arm FITC bPEG 40kD-PEG-FITC 25 mg/mL 
80kD 7-arm NHS, 1-arm FITC star PEG 80kD-PEG-FITC 50 mg/mL 
 
 
 
 
4.2  PEG-Treatment of Islets 
 
 
 
 Islets were modified by the following method with one of five PEG molecules.  Table I 
shows the concentration used for each type of PEG.All PEG solutions were prepared with 11mM 
glucose solution in PBS immediately before addition to islets.  Islets were collected into an 
appropriate vessel half full with HBSS+FBS.  Choice of container depended on the number of 
islets to be modified.  The contents of the tubes were washed three times with 4 mM glucose 
solution.  The islets were pelleted by centrifugation and as much supernatant was removed as 
possible.  Freshly prepared PEG solution was added to each tube containing islets.  The reaction 
was allowed to proceed at 37 C for 30 min.  Following the incubation the islets were washed 3 
times with 4 mM glucose in PBS + 10% FBS.  Islets to be used for confocal microscopy were 
fixed for 20 min at room temperature in 0.1 % paraformaldehyde.  Islets used for the transplant 
study and the quantitative antibody binding assay remained in the reaction tubes for further 
manipulation. 
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 4.3  Confocal Microscopy 
 
 
 
4.3.1  Imaging Surface Bound PEG 
 
 
 
 To determine, qualitatively, the nature of PEG-binding at the islet surface, islets were 
treated with 5kD-PEG-FITC, 40kD-PEG-FITC, or 80kD-PEG-FITC as described above then 
imaged with a Molecular Dynamics confocal microscope.  Unless otherwise noted, images were 
collected at 60x magnification with a pixel size of 0.34um. 
 After collagenase digestion to separate islets from their native matrix, the islet capsule 
may be damaged or entirely absent.  To determine whether or not the presence of a capsule 
affected the quality of PEG binding, islets were isolated and treated with PEG after one, four or 
six days in culture, then imaged as described above. 
 
 
 
4.3.2  Two Color Imaging of PEG and Antibody Binding 
 
 
 
 Islets were collected after six days in culture.  Half were treated with 80kD-PEG-FITC as 
described above.  The rest were left untreated.  Both groups were then incubated for 2 hours at 
room temperature in rabbit anti-rat islet antiserum (Chemicon special order).  The islets were 
washed 3 times in 11mM glucose + 10% FBS.  They were then incubated with anti-rabbit IgG-
Cy3 (Molecular Probes) diluted to 0.05 mg/mL in 11mM glucose.  They were washed three 
times with 11 mM glucose + 10% FBS, then fixed for 20 min at room temperature with 1% 
paraformaldehyde.  The islets were imaged using a confocal microscope operating in two color 
mode. 
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 4.4  Quantitative Antibody Binding Assay 
 
 
 
 Islets were collected after six days in culture.  Islets from each rat were divided into two 
equal groups.  One group was treated with either 5kD-PEG or 40kD-PEG.  The other group was 
left untreated.  Both groups were then incubated with a 1:10 dilution of rabbit anti-rat islet 
antiserum at room temperature for 2 hours.  The islets were washed 3 times with 11 mM glucose 
+ 10% FBS.  They were then incubated in a 1:1000 dilution of horseradish peroxidase 
conjugated goat anti-rabbit IgG secondary antibody, also for two hours at room temperature.  
The islets were washed two times with 11 mM glucose + 10% FBS, pelleted, then transferred to 
separate Petri dishes.  From the Petri dishes, groups of 100 islets were manually counted and 
transferred to 0.7 mL Eppendorf tubes.  The islets were washed once more with 11mM glucose 
+10% FBS and the supernatant was removed.  200 uL TMB (Mercodia) substrate was added to 
each tube.  The substrate was allowed to react for 15 min at room temperature.  The reaction was 
quenched by addition of 50 uL of 2M H2SO4.  100 uL of supernatant was removed from the 
reaction tubes and transferred to wells of a 96 well microtiter plate.  The absorbances, at 450 nm, 
of the supernatants were read with a microplate reader with the reference wavelength at 650 nm.  
Results were analyzed using the student’s paired t-test. 
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 4.5  Islet Allograft Transplantation 
 
 
 
4.5.1  Induction of Diabetes 
 
 
 
 Adult, male, 250–350 g Brown Norway rats served as hosts for islet transplants.  
Diabetes was induced by injection of 60 mg/kg of streptozotocin (STZ) via the tail vein.  The 
STZ solution was prepared at a concentration of 35 mg/mL in ice cold, sterile citric acid/citrate 
buffer (pH 4.5).  Body weight and blood glucose concentration were monitored daily following 
induction and diabetes was confirmed by blood glucose above 300 mg/dL. 
 
 
 
4.5.2  In Vitro Islet Function 
 
 
 
 To ensure that islets were functioning prior to transplant they were tested using a static 
glucose challenge assay.  Islets were collected, counted into groups of twenty, and transferred to 
separate 0.7 mL eppendorf tubes.  Islets were washed three times in 4.4 mM glucose in PBS + 
0.25% human albumin (low glucose solution).  Islets were incubated for 25 min at 37 C with 
gentle agitation every 5 min.  Islets were pelleted and 50 uL supernatant was removed from each 
tube and transferred to new 0.7 mL eppendorf tubes.  Islets were washed two times with low 
glucose solution.  Then the islets were incubated for 25 min in 16.7 mM glucose in PBS + 0.25% 
Human albumin (High glucose solution) at 37 C.  Again 50 uL aliquots from each tube were 
collected and transferred to new tubes.  The islets were washed twice with low glucose solution 
then incubated once more for 25 min at 37 C in low glucose solution.  The islets were pelleted 
and supernatants were collected to assay for insulin.  Supernatants insulin concentration was 
determined using a commercially available rat-insulin enzyme-linked immunoassay (ELISA) kit 
(Mercodia).   
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 4.5.3  Islet Transplantation 
 
 
 
 After confirmation of diabetes in the host rats, islet transplants were performed within 
three days.  The host animal was anaesthetized with a cocktail of ketamine (~0.35 cc) and 
xylazine (0.04 cc).  The abdomen was shaved and washed with 70% ethanol.  A small midline 
incision was made in the skin of the abdomen and the underlying abdominal wall.  The graft of 
~4,000 islets was transferred to the peritoneal cavity via pipette in 0.5 mL carrier (PBS + 0.25% 
human albumin).  The albumin was utilized to reduce adherence of the islets to hydrophobic 
surfaces during the procedure.  Four rats received untreated islet grafts.  Four received grafts 
treated with 5kD-PEG.  One rat was sham-operated as a negative control.  Blood glucose and 
body weight were monitored daily until graft failure, indicated by return of blood glucose 
concentration to above 300 mg/dL.  Host rats were euthanized following graft failure by 
exsanguination under anesthetic.16,17,40 
 
 
 
 
4.6  In Vivo Islet Function 
 
 
 
 Three to four days following graft placement, the ability of the grafts to respond to a 
spike in blood glucose was tested.  Food was withheld 90 minutes prior to the experiment.  The 
rats were anesthetized by intramuscular injection of ketamine (0.35 cc).  Xylazine could not be 
used during this procedure as it elevates the resting blood glucose level and thus would have 
impacted the results.  A baseline measurement of the blood glucose level was taken.  The rats 
were given an IV bolus of 1.5 g/kg glucose solution (0.5g/mL in PBS).  Blood glucose 
measurements were then taken at 0, 15, 30, 60, 90 and 150 min. 
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5.0  RESULTS 
 
 
 
 
5.1  Islet Isolation 
 
 
 
 After collagenase digestion, the collagenous islet capsule was partially or completely 
destroyed, though after several days in culture the capsule was capable of regenerating.  Initially 
an isolation method was used that included two serial density gradient separations.  It was found 
that the purity of islets prepared this way was not consistently high enough to allow culture for 
more than one night.  For this reason modifications were made to the isolation procedure.  By 
eliminating the second density gradient separation and instead handpicking the islets from the 
remaining exocrine tissue, purity was improved to allow longer culture time, and yield was 
improved three to four times over the previous method. 
 
 
 
 
5.2  Confocal Images 
 
 
 
5.2.1  Effect of Increased Culture Time on Quality of PEG Binding 
 
 
 
 Originally, it was hypothesized that if PEG was bound to the islet capsule, it may act as a 
perm-selective barrier and prevent cellular and molecular components of the immune system 
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 from access to the islet cells.  It was also believed that this would be a longer-lasting 
modification than if PEG was bound to islet cell surface markers which might be rapidly 
recycled.  Considering the questions surrounding the issue of PEG binding in previous research, 
and after learning that the capsule is destroyed during collagenase digestion, we felt that it was 
important to clarify these issues and to determine the effect of the capsule on the PEG 
modification process. 
 Figure 1 shows images of three islets from groups isolated one, four and six days prior to 
modification with 80 kD FITC-PEG.  The images are maps of the intensity of light collected at 
535 nm portrayed in pseudocolor.  Red and white indicate high intensity, blue is low intensity 
and black represents signal below the threshold.  Before interpreting the images obtained by 
confocal microscopy, it is important to note that the signal collected varied from experiment to 
experiment.  Factors affecting the overall signal include: increased background fluorescence 
from FITC-PEG in solution, photobleaching from exposure to light, reduced activity of amine- 
reactive PEG due to slow dissolution of PEG powder and hydrolyzation of the amine-reactive 
moiety in water.  For these reasons, quantitative comparisons of images from different 
experiments are not valid.  Images have been selected to reflect trends observed. 
 It is important to note from Figure 1, that as the islets are allowed time in culture, the islet 
periphery becomes smoother.  This indicates regeneration of a layer of extracellular matrix 
surrounding the islet.  The images also show that when this protein layer is present, it does react 
strongly with amine-reactive PEG. 
 
 
 
5.2.2  Effect of PEG Molecular Weight 
 
 
 
 During the course of the research, three structural variants of the PEG molecule were 
employed: a small linear molecule (5 kD PEG), a medium-sized branched molecule (40 kD 
PEG), and a larger star-shaped molecule (80 kD PEG).  The qualitative variation in the binding 
of these PEG variants was investigated with fluorescence microscopy. Figure 2 shows images of 
three islets all from one isolation group, modified with one of the three different PEG molecules.  
It was hypothesized that as PEG molecular weight increased, the amount of PEG that was able to  
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Figure 1.  Effect of Culture Time on PEG-Binding. 
Image in lower left is 6-day-old  untreated islet  for reference.  Remaining islets were treated with 80 kD FITC-PEG 
after varying time in culture.  Clockwise from upper left, islets were treated 1, 4, and 6 days following isolation.  
The width of the scale box in the lower left of each image equals 5 um. 
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Figure 2.  Effect of PEG MW on PEG binding. 
Three images of 6-day-old islets modified with three different PEG-molecules. Islets were treated with A) 5 kD 
FITC-PEG, B) 40 kD FITC-PEG and C) 80 kD FITC-PEG. 
 
 
 
 
 
 
Figure 3.  Determining appropriate Ab treatment for Ab-binding experiments. 
Images are: A) unmodified islet incubated with anti-islet antiserum and FITC-secondary Ab, B) unmodified islet 
incubated with control non-clonal primary Ab and FITC-secondary Ab, C) unmodified islet no Ab treatment. 
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 diffuse to the center of the islet would decrease.  The images show, to the contrary, that in the 
range investigated, there was little if any relationship between diffusion and molecular weight.  
In all three images, staining of individual islet cells is apparent throughout the islet volume.  
Compare these images to the negative control in Figure 1.  The gain for the negative control 
image was increased to the point that it was possible to discern the islet background 
autofluorescence.  In contrast, the gain for the images of PEG-modified islets was much lower.  
In these images, the circumference of each islet cell is discernible, and there is very little staining  
in the centers of individual cells.  This indicates that for all three PEG configurations, a 
significant amount of PEG is diffusing throughout the islets. 
 
 
 
 
5.3  Confocal Microscopy of Bound Antibody 
 
 
 
 Prior to completing any qualitative or quantitative antibody binding assays, it was 
necessary to find an antibody treatment that would label the islets strongly and act as a suitable 
positive control.  Strong labeling was achieved after incubation first with rabbit anti-rat islet 
antiserum then with donkey anti-rabbit IgG – FITC.   Figure 3 shows images of typical islets.  
The top left image is an un-modified islet incubated with full strength rabbit anti-rat islet 
antiserum followed by the fluorescein-labeled secondary antibody.  Note the strong staining at 
the islet periphery.  The remaining two images are negative controls.  The upper right image is 
an unmodified islet incubated with a solution of non-clonal rabbit IgG followed by the secondary 
antibody.  The final image is an unmodified islet not incubated with any immunological reagents.  
The negative control images show that non-specific staining and the islet background 
autofluorescence do not account for the staining observed in the antiserum group. 
 Figure 4 shows images of three islets that were modified first with 80 kD PEG-FITC then 
treated with anti-islet antiserum followed by Cy3 labeled secondary Ab.  The green channel 
represents areas where PEG is bound.  The red signal represents bound Ab.  The PEG coating in 
these images appears patchy, but this may be due to the operating mode of the microscope used 
to capture the images.  Specifically, the microscope that captured single color images scanned 
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Figure 4.  Simultaneous, two-color PEG/Ab images. 
Images of 6-day-old islets modified with 80 kD FITC-PEG then incubated with anti-islet antiserum followed by Cy3 
labeled secondary Ab.  Red represents Ab, Green represents PEG. 
27 
 the islets twice and averaged the signal from the two scans.  The microscope that captured  the 
two-color images scanned the islets a total of eight times per image.  Since fluorescein is less 
photostable than Cy3, the green signal was likely attenuated by photobleaching.  Nonetheless, it 
should be apparent that there are regions on the islet surface where PEG and bound Ab coincide. 
 
 
 
 
5.4  Quantitative Ab-Binding Data 
 
 
 
 To determine quantitatively, the ability of PEG to prevent Ab binding at the islet surface, 
a modified ELISA assay was used.  Figure 5 shows the results of the binding assay using 
untreated and 40 kD PEG modified islets.  The data is presented in pairs with the untreated 
groups in the left column and the treated groups in the right.  Groups of islets isolated on the 
same day and from the same animal were paired. Absorbance measurements are directly related 
to the concentration of converted chromogenic substrate, which is in turn related to the amount 
of Ab bound to the islet surfaces.  It is clear from the chart that 40 kD PEG treatment does not 
reduce Ab binding.  In fact a statistical increase in Ab binding was found for PEG-treated islets, 
suggesting that by some mechanism, this treatment increases the amount of bound antibody.   
 The assay was also run using 5 kD PEG treated islets.  Figure 6 shows the results of this 
experiment.  Although this is not a significant result, the data does suggest that reacting the islet 
with this type of PEG had some effect on the quantity of Ab that is able to bind.  In seven of the 
nine trials, the PEG group bound less antibody than the untreated group. 
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Figure 5.  Results of Ab-binding assay for 40 kD PEG-treated islets. 
Absorbance at 450 nm is directly related to quantity of Ab-bound.  Data appear as paired groups. 
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Figure 6.  Results of Ab-binding assay for 5 kD PEG-treated islets. 
Absorbance at 450 nm is directly related to quantity of Ab-bound.  Data appear as paired groups. 
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 5.5  In Vitro Islet Function 
 
 
 
 To verify that islets were still functioning and could respond to a spike in ambient 
glucose concentration, a static glucose challenge assay was performed.  It was hypothesized that 
islets would release more insulin in the high concentration glucose solution than in the low 
concentration glucose solution.  The results of the first run of this experiment bore out the 
hypothesis.  High glucose supernatants contained ~5ug/mL more insulin than the low glucose 
supernatants (data not shown).  After this positive result and evidence from a pilot islet 
transplantation study that the islets were functioning properly in vivo, this in vitro experiment 
was considered unnecessary and isolated islets were instead reserved for the transplants. 
 
 
 
 
5.6  In Vivo Islet Graft Survival 
 
 
 
 As a final test of the effectiveness of PEG modification for immunoprotection of 
pancreatic islets, this strategy was investigated in vivo.  Figure 7 shows the results of the 
transplant study.  Similar responses were observed from both the untreated and the PEG-treated 
islet grafts.  Blood glucose concentration and body weight were tracked from the day before the 
transplant until graft failure was confirmed.  In all animals, significant reduction of blood 
glucose concentration was observed after 2–4 days.  Weight loss was reversed sometimes after 
one day and always before 3 days following transplant. 
 Elevation of blood glucose concentration was generally observed after seven days and 
full return of the hyperglycemic state always occurred between eight and nine days following the 
transplant.  Due to lack of any observable effect, the experiment was discontinued. 
30 
 C h a n g e  in  b o d y  m a s s  fo l lo w in g  is le t  t r a n s p la n ta t io n
2 0 0
2 2 0
2 4 0
2 6 0
2 8 0
3 0 0
3 2 0
3 4 0
3 6 0
-3 -1 1 3 5 7 9 1 1
P o s to p e r a t iv e  D a y
B
od
y 
M
as
s 
(g
)
C o n tro l # 1
C o n tro l # 2
P E G  # 1
P E G  # 2
Change in Blood Glucose Concentration follow ing Islet 
Transplantation
0
50
100
150
200
250
300
350
400
450
500
-2 0 2 4 6 8 10 12
Postoperative Day
B
lo
od
 G
lu
co
se
 C
on
ce
nt
ra
tio
n 
(m
g/
dL
)
Control #1
Control #2
PEG #1
PEG #2
 
 
 
Figure 7.  Changes in blood glucose concentration and body mass following pancreatic islet transplantation. 
Elevation of blood glucose concentration above 300 mg/dL and reduction in mass at day 8 were considered 
evidence of graft failure in all animals. 
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6.0  DISCUSSION 
 
 
 
 
6.1  Confocal Images of Bound PEG 
 
 
 
After making adjustments to the previously applied imaging protocol employed by Susan 
Dadd35, namely by scanning with greater lateral resolution and capturing with a more powerful 
objective lens, it was possible to obtain higher resolution images and to discern individual islet 
cells within the islet volume with confocal microscopy.  From these images it became clear that 
although the collagenous capsule does provide a good substrate for covalent modification, it does 
not prevent diffusion of large molecules into the islet interior.  This suggests that treatment of 
just the capsule is not sufficient to prevent acute rejection of the pancreatic islets, as islet specific 
antibodies and inflammatory cytokines may still infiltrate into the islets.  However, as the PEG 
was able to penetrate the islets, good labeling of individual islet cell surfaces was observed, and 
presence of PEG here may be beneficial, since although permeation of immunologic molecules 
may not be prevented, their binding might be blocked. 
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 6.2  Quantitative Ab-Binding Assay 
 
 
 
 After observation of confocal images of islets treated either with fluorescent PEG or with 
a fluorescent secondary antibody, it was obvious that in some instances the fluorophore was 
present inside individual islet cells.  This is evidence that these cells are dead and thus are more 
permeable to large molecules (figure 8).  This is important to keep in mind when interpreting 
data from the quantitative antibody binding assay.  Islet cell necrosis would depend on such 
factors as time in culture, purity of the islet preparation and degree of collagenase digestion, and 
would be difficult to predict.  Due to the fact that necrotic regions of the islets were likely to 
become saturated with secondary antibody, and that a relatively low number of islets contained 
large necrotic regions, this may have artificially elevated measurements of islet-specific, bound 
antibody in some but not all experimental groups.  Specifically, in the antibody binding assay for 
 
 
 
  
 
 
Figure 8.  Images showing presence of putative necrotic regions. 
A)Image of islet modified with flourescent PEG, B)Image of islet modified with PEG then treated with anti-islet 
antiserum and flourescent secondary antibody.  Circled areas appear to be permeabilized islet cells, which have 
become saturated with the respective flourescent marker 
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 5kD PEG-treated islets, of nine paired groups, seven showed reduced antibody binding from the 
untreated control.  It may be that in the two groups that did not follow the trend, a greater 
number of PEG-treated islets contained significant regions of necrosis, in which case the reading 
taken would not accurately reflect the amount of islet-specific bound antibody.  Although the 
results of this experiment were not statistically significant, it seems likely that there is some 
potential for PEG to reject specific antibody binding to pancreatic islets. 
 
 
 
 
6.3  In Vivo Transplantation Study 
 
 
 
 The results from the in vivo islet transplantation study suggest that covalent modification 
with 5kD PEG does little to prevent acute rejection of transplanted allotypic pancreatic islets.  It 
may be that the surface PEG layer is simply not a robust enough barrier to prevent access to the 
islet by the various components of the host immune system.  However, certain factors for 
successful islet transplant could not be satisfied given the limited resources available for this 
research.  For instance, choice of implant site was governed by the technical limitations of the 
researcher.  Sites more suitable for islet transplant might be the portal vein or under the kidney 
capsule.41,42  Additionally, it has been observed that transplantation of a greater number of islets 
often leads to a more successful result.43,44  Due to limitations of time it was not possible to 
prepare a sample of more than 4,000 islets for each transplant.  Although this graft size was 
sufficient to reverse diabetes initially, the rapid reversion to the diabetic state may have been due 
to a less than ideal number of islets per graft.  This research thus does not clearly eliminate 
covalent modification of pancreatic islets with PEG as a way to shield this transplanted tissue 
from the host immune system, but the transplant protocol as it was performed does not clearly 
suggest that this approach would be a clinically feasible solution to IDDM. 
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 6.4  Future Directions 
 
 
 
 Perhaps the most fruitful approach involving covalently bound PEG will be to combine 
this technique with other chemical or biological means to modify the immune response.  One can 
envision PEG as a molecular tether to immobilize slow release vesicles or genetically altered 
cells that would release anti-inflammatory cytokines locally at the islet surface.  Polyfunctional 
PEG could also serve as a foundation for a more extensive PEG microstructure, which could 
provide a diffusion barrier as well as containing cells or drug-delivery vehicles.  As it has been 
shown to have little effect on viability or function of pancreatic islets, 25,26 and since it may have 
the effect of limiting antibody binding, this technique warrants further attention as a means of 
immunoisolating pancreatic islets. 
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Appendix A 
 
 
 
Additional Islet Images 
 
 
 
 
 
Figure 9.  Images of islets modified with 80kD PEG-FITC 
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Figure 10.  Images of islets modified with 40kD PEG-FITC, after six days in culture. 
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Figure 11.  Images of islets modified with 5kD PEG-FITC. 
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